Ansun Biopharma is a late-stage clinical development company dedicated to saving the lives of vulnerable patient populations through the creation of first-in-class biologics. Our lead product, DAS181, is a multi-function sialidase fusion protein for host-cellprotection in respiratory virus infection, including parainfluenza, influenza and COVID19,. We are also advancing several additional programs in oncology and autoimmune diseases using our sialidase platform technology.
Location: United States, California, San Diego
Employees: 11-50
Total raised: $85M
Founded date: 2003
Investors 2
| Date | Name | Website |
| - | 3E Biovent... | 3ebiovc.co... |
| 09.02.2022 | Matrix Par... | matrixpart... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 14.05.2018 | Series A | $85M | - | finsmes.co... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 15.10.2019 | Chinese biotech firm Ansun BioPharma secures $80m Series B f... | Premium Chinese biotech firm Ansun Biopharma has announced the completion of a 56 million yuan ($80... | dealstreet... |
| 16.05.2018 | Term Sheet — Wednesday, May 16 | CRYPTO UNICORN Good morning, Term Sheet readers. Paid Content You can't secure what you can't see ... | fortune.co... |
| 14.05.2018 | Ansun BioPharma Secures $85M in Series A Financing | Ansun BioPharma, Inc., a San Diego, CA-based biotechnology company focused on the development of nov... | finsmes.co... |